GLPwatch
Papers (12034)
Page 141 of 201, ranked by citation count.
- The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus.
- RYGB induces vagal sensory neuropathy characterized by altered Glp1r expression and enhanced exendin-4 responsiveness in male mice.
- [The incretin effect and type 2 diabetes].
- Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A <i>Post Hoc</i> Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial.
- Glucagon-like peptide-1 receptor PET/CT with <sup>68</sup>Ga-exendin-4 for localizing insulinoma: a real-world, single-center study.
- The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes.
- Exendin-4 imaging based on gastrointestinal GLP-1R targets for IBD diagnosis and efficacy assessment.
- Peptide-Coated Polycaprolactone-Benzalkonium Chloride Nanocapsules for Targeted Drug Delivery to the Pancreatic β-Cell.
- Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight.
- Obstructive Sleep Apnoea Treatments-Where Are We Now?
- Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study.
- Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.
- From Prescription to Predicament: A Case of Semaglutide-Induced Discoid Lupus Erythematosus in an Adult Male Patient.
- Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.
- Eczematous liraglutide eruption managed by dupilumab: A case report.
- Idiosyncratic acute liver failure induced by Tirzepatide.
- Relationship of vascular complications and exenatide therapy failure in type 2 diabetic patients.
- First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss.
- Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF: Evidence for Synergistic Benefit with GLP-1/Glucagon Agonism.
- Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients.
- Insulin release from isolated cat islets of Langerhans.
- Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes.
- A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass.
- Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report.
- Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study.
- Impact of Semaglutide on Limb Events: A Meta-Analysis of Randomized Controlled Trials.
- Effects of patient age on the therapeutic effects of GIP/GLP-1 receptor agonists (tirzepatide).
- Advantage of Semaglutide: Comprehensive Analysis of Metabolic Impact of Semaglutide-Treated and Pair-Fed Rats.
- Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.
- Safety and Effectiveness of Tirzepatide Use in Obesity Without Type 2 Diabetes Mellitus.
- A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide.
- [A new era for glucagon-like peptide-1 receptor agonists].
- Convergent Metabolic Pathways in MASH Therapeutics: An AMPK-Centric Analysis.
- Comparative cardiovascular effects of GLP-1 agonists using real-world data.
- Tirzepatide Affect Sexual Function in Women: Case Report.
- In persons with obesity, exercise plus liraglutide improved weight-loss maintenance vs. exercise or placebo.
- Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide.
- Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
- Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis.
- Reduced incretin receptor trafficking upon activation enhances glycemic control and reverses obesity in diet-induced obese mice.
- Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes.
- Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
- The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery.
- The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous?
- Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial.
- Effects of all-trans retinoid acid and exendin-4 on islet transplantation in NOD mice.
- Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes.
- Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study.
- Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis.
- Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis.
- Dissecting Hidden Liraglutide Oligomerization Pathways via Direct Mass Technology, Electron-Capture Dissociation, and Molecular Dynamics.
- U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT Trial.
- Renal effects of exendin-4 in an animal model of brain death.
- Is semaglutide cost-effective at closing the gap for Aboriginal and Torres Strait Islander Australians with cardiovascular disease and obesity without type 2 diabetes?
- Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.
- Response to semaglutide of non-drinker subjects with type 2 diabetes.
- Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database.
- Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study.
- Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes.
- Maturity-Onset Diabetes of the Young (MODY) With HNF1B p.Glu105Lys Mutation Achieving Significant Insulin Reduction on Tirzepatide: A Case Report.